by François Briand | Mar 3, 2024 | 2024
iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models – check the poster content here If you are interested to evaluate your novel therapies with Physiogenex, feel free to contact us to discuss your next...
by François Briand | Jan 30, 2024 | 2024
HepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4 mouse model of liver fibrosis. Review the manuscript here. If you also wish to demonstrate the efficacy of your therapies in Physiogenex models, feel free to...